Ready to start planning your care? Call us at 800-525-2225 to make an appointment.





Find and Mark Appetention Garner Specialist

Madert 2018 Autie Otentoreen & Treatment

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

Brain Tumors

Drug Development

View all ¥



Dr. Mellinghoff's Office Information ➤



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

•

Call 212-639-6767

Make an appointment

About Me

Ingo K. Mellinghoff 1/8

What I Do at MSK

- Chair, Department of Neurology
- Chief, Brain Tumor Service
- Evnin Family Chair in Neuro-Oncology

Get To Know Me

I am a medical oncologist specializing in the diagnosis, treatment, and management of central nervous system (CNS) tumors, with a focus on low-grade glioma and glioblastoma.

As Chair of the Department of Neurology, I lead a team of experts in neuro-oncology, neurology, clinical neurophysiology, clinical neuropsychology, and rehabilitation medicine. We evaluate and treat people with all types of primary brain tumors (tumors that start in the brain). We also care for patients with brain metastases or leptomeningeal (LEP-toh-meh-NIN-jee-ul) metastases from other cancers, neurologic effects of cancer or its treatment, and a broad range of conditions requiring physical rehabilitation.

Read more

+

My Role at MSK

A neuro-oncologist is a doctor with special training in cancers that affect the brain, spinal cord, peripheral nerves, and muscles. This includes brain tumors and central nervous system tumors.

Areas of Expertise

My Specialties

Brain Tumors

Drug Development

Education & Honors

Education

MD, Technische Universität Műnchen

Residencies

Internal Medicine - University of California, Los Angeles
Chief Resident Internal Medicine, University of California, Los Angeles

Ingo K. Mellinghoff 2/8

Awards and Honors

Castle Connolly: Top Doctors (2020-2024)

Top Doctors New York Metro Area, Castle Connolly (2023)

Clarivate List of Highly Cited Researchers (2021-2023)

New York Magazine: Top Doctors (2021-2022)

Associate Editor, Journal of Clinical Oncology (2012-2022)

Neuro-Oncology Scientific Award, American Academy of Neurology

Member (elected), Association of American Physicians

Fellow, American College of Physicians

Outstanding Investigator Award (R35), National Institute of Neurological Disorders and Stroke (NINDS)

Member (elected), American Society of Clinical Investigation

Advanced Clinical Research Award in Glioma, American Society of Clinical Oncology (ASCO)

Translational Science Award, Sidney Kimmel Foundation

Distinguished Scientist Award, Sontag Foundation

Fellowships

Medical Oncology and Hematology - University of California, Los Angeles

Board Certifications

Internal Medicine

Medical Oncology

Hematology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Enter your insurance provider

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our <u>financial assistance</u> programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Ingo K. Mellinghoff 3/8

Make an Appointment



New Patients

Scheduling an appointment is easy. Click or call 212-639-6767— we're available Monday through Friday, 8 a.m. to 6 p.m. (Eastern time)

Make an Appointment

Ingo K. Mellinghoff 4/8

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor's office. If you aren't registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Mellinghoff sees patients at one location.

Patients & Clinical



646-888-3036

Location



New York, NY

Rockefeller Outpatient Pavilion



160 East 53rd Street New York, NY 10022 **Get Directions**

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Ingo K. Mellinghoff 5/8



Clinical Trials

Clinical Trials Investigated by Dr. Mellinghoff

A Phase I Study of Vorasidenib with Pembrolizumab Immunotherapy for Recurrent or Persistent IDH-1 Mutant Astrocytomas

A Phase II/III Study of Regorafenib, Paxalisib, and VAL-083 versus Standard Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma (GBM AGILE)

A Study of ERAS-801 in People with Glioblastoma That Came Back After Treatment

Clinical Trials Co-Investigated by Dr. Mellinghoff

A Phase I/II Study of Ibrutinib in Patients with Recurrent or Persistent Central Nervous System (CNS) Lymphoma

Read more



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials



Research and Publications

View Dr. Mellinghoff's Lab

Publications on PubMed

Visit PubMed for a full listing of Dr. Mellinghoff's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed



Ingo K. Mellinghoff 6/8

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ingo K. Mellinghoff discloses the following relationships and financial interests:

American Society of Clinical Oncology (ASCO)

Professional Services and Activities

Black Diamond Therapeutics, Inc.

Professional Services and Activities

Doris Duke Charitable Foundation

Professional Services and Activities

Roche

Professional Services and Activities

Servier

Professional Services and Activities

Voyager Therapeutics Inc.

Professional Services and Activities

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

View all disclosures



Connect

Ingo K. Mellinghoff 7/8

Contact us
<u>Locations</u>
APPOINTMENTS
800-525-2225
About MSK
About us
<u>Careers</u>
Giving ■
Cancer Care
Adult cancer types
Child & teen cancer types
Integrative medicine
Nutrition & cancer
Find a doctor
Research & Education
Sloan Kettering Institute
Gerstner Sloan Kettering Graduate School
Graduate medical education
MSK Library. ■
Confidence Control of the Control of
Cookie preferences Legal disclaimer
Accessibility statement
Privacy policy
Price transparency
Public notices
© 2024 Memorial Sloan Kettering Cancer Center

Ingo K. Mellinghoff 8/8